Association of serum VLDL level with hyperhomocysteinemia in hypertensive patients: A cross-sectional study

Jian Chen1,2, Jing Li2, Jia Wang2

  • 1University of South China , Hengyang, China.

Insights

High very low-density lipoprotein (VLDL) levels are linked to increased risk of hyperhomocysteinemia (HHcy) in hypertensive patients. This association is independent of other risk factors, suggesting VLDL as a potential indicator for this condition.

Area of Science:

  • Cardiovascular Disease Research
  • Metabolic Syndrome Studies
  • Clinical Biochemistry

Background:

  • Hyperhomocysteinemia (HHcy) and hyperlipidemia are independent cardiovascular disease risk factors.
  • The relationship between hyperlipidemia and HHcy in hypertensive individuals remains under-investigated.
  • Very low-density lipoprotein (VLDL) is a key component of hyperlipidemia.

Purpose of the Study:

  • To investigate the association between very low-density lipoprotein (VLDL) and hyperhomocysteinemia (HHcy) in hypertensive patients.
  • To determine if VLDL is an independent contributor to HHcy in hypertension.

Main Methods:

  • A large cross-sectional study involving 4012 participants from Hunan province, China (July 2013–March 2014).
  • Assessment of lipid profiles, homocysteine (Hcy) levels, anthropometrics, blood pressure, and biochemical indicators.
  • Statistical analysis including univariate and multivariate logistic regression, adjusting for confounding variables.

Main Results:

  • Among 1257 hypertensive participants, 86% had HHcy.
  • Higher quartiles of Log VLDL were significantly associated with increased odds of hypertension with HHcy (OR=3.7, P<.001).
  • Each unit increase in Log VLDL was associated with a 1.3-fold increased risk of hypertension with HHcy (P<.001), independent of other factors.

Conclusions:

  • Log VLDL concentration is an independent risk factor for hypertension associated with HHcy.
  • VLDL may serve as a potential diagnostic and prognostic marker for this condition.
  • Further research is needed to explore the therapeutic implications of VLDL levels in managing hypertension with HHcy.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
478
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
346
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
412
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
577
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
330
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
442